Clinical trials

Kiave Yune Ho Wang Yin, PhD, Chief Business Officer at Transure Bioservices explores how humanized mouse models can be used to develop more relevant preclinical studies for IBD treatments and ultimately increase the likelihood of a treatment’s success in clinical trials.  Inflammatory bowel diseases (IBDs), including Crohn’s disease and ulcerative colitis (UC), are a global […]

Eurofins Genomics has adopted Olink technology to advance proteomics research and accelerate its precision medicine programmes. The collaboration is designed to bolster the company’s offerings in the fields of research, population health, and regulated clinical trials. Olink Explore HT is the company’s latest solution for high-throughput proteomics, allowing scientists to accurately measure over 5,300 proteins […]

Integrated drug formulation and clinical trials company, BDD Clinical Trials, has secured a further round of investment for £2M to aid the company’s expansion in response to growing demand for both its patented drug delivery technology and specialist clinical trial services.  The latest investment package follows a strong 18 months for the company, which more […]

DDW’s Diana Spencer highlights five key clinical studies taking a new therapeutic approach to childhood cancers. Over 100 subtypes of childhood cancer exist today and it represents the most common cause of disease-related death in children. However, despite the fact that children’s response to adult cancer drugs is often poor, due to the challenges of […]

A new whitepaper has introduced the concept of ‘cross-over’ options in cancer clinical trials, as a way to make trials more patient-centric in design. ‘Cross-over arms in oncology clinical trials: An important consideration for patients’ was published by the Cholangiocarcinoma Foundation (CCF) with the aim of opening new doors for patients with limited treatment options. […]

Accurate dose prediction for clinical trials is essential to ensure patient safety and trial success. This new whitepaper from the Jackson Laboratory discusses evidence-based selection of starting doses in first-in-human clinical trials through the utilisation of humanised mouse models. In this whitepaper you will learn about: The significance of selecting appropriate starting doses in clinical trials. […]

This whitepaper discusses evidence-based selection of starting doses in first-in-human clinical trials through the utilisation of humanised mouse models and emphasises the importance of accurate dose prediction to ensure patient safety and trial success. In this whitepaper you will learn about: The significance of selecting appropriate starting doses in clinical trials. Utilising humanised mouse models […]

Educational campaign, Clinical Trials For All, has been launched to drive greater understanding, participation and diversity in clinical trials. Only 59% of Americans know about clinical research, 91% of Americans have never been invited to participate, and Black/African and Hispanic/Latino Americans are less than 12% of participants. “Clinical research isn’t what many people think it […]

This is the latest episode of the free DDW narrated podcast, “What lies in the future for genomics and big data?”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “US biotech: Focus on positive growth and innovation”, and “Sitting down with Calidi Biotherapeutics”. In the […]

DDW’s Reece Armstrong speaks to Shantanu Dhamija, VP of Strategy and Innovation at Molecular Devices about challenges of diversity in clinical trials and why induced pluripotent stem cells might be key to representing wider patient groups.   RA: Why is US clinical trial diversity at its lowest point in the last 10 years?   SD: The […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The most impactful drug discovery news this week is all linked with scientific research data. Analysts Phesi revealed that a third of clinical […]

News round-up for 17-21 July by DDW Digital Content Editor Diana Spencer. The most impactful drug discovery news this week is all linked with scientific research data. Analysts Phesi revealed that a third of clinical development programmes are cancelled during Phase II, and there were significant trial results for drugs for head and neck cancer […]

Eli Lilly has announced positive results of the TRAILBLAZER-ALZ 2 Phase III study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease.   Donanemab met the primary endpoint of change from baseline until 18 months on the integrated Alzheimer’s Disease Rating Scale (iADRS). The primary endpoint of iADRS […]

ICON, a healthcare intelligence and clinical research organisation, recently released its ICON Cares 2022 Environmental, Social and Governance (ESG) Report. Diarmaid Cunningham, Chief Administrative Officer at ICON, shares insight with DDW.  At ICON, we engage with our key stakeholders through a variety of methods and the environmental, social and governance (ESG) report is a key […]

Analysis of 13,490 clinical trials finds almost a third have been cancelled during Phase II amidst an overall decline in clinical development productivity. Data analytics company Phesi has released the results of its mid-year global analysis of all clinical trials conducted in 2023 to date. The analysis reveals that Covid-19 is no longer one of […]

Sequana Medical, a company targeting fluid overload in liver disease, heart failure and cancer, has enrolled the first patient in its MOJAVE study.  MOJAVE, a randomised controlled Phase I/IIa study in the US, will evaluate the safety and efficacy of the company’s second-generation DSR product (DSR 2.0) in diuretic-resistant chronic heart failure patients with persistent […]